Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21543268 | 0.61 | MEN1 (0.43) | NPC1RAB9APOLBATM | |
| SCHEMBL25302734 | 0.61 | IGF1R (0.32) | LMNACDK8MAPK14MAPK13MAPK12 | |
| SCHEMBL17836029 | 0.60 | MEN1 (0.42) | LMNANPC1RAB9APOLBGAA | |
| SCHEMBL5847269 | 0.59 | ENPP3 (0.33) | NPC1RAB9APOLBGAA | |
| SCHEMBL27228493 | 0.58 | MAPT (0.34) | LMNAPOLB | |
| SCHEMBL28719439 | 0.58 | NPC1 (0.47) | LMNANPC1RAB9ASERPINE1 | |
| SCHEMBL18702740 | 0.58 | NR1H4 (0.56) | LMNANPC1RAB9ASERPINE1 | |
| SCHEMBL26607478 | 0.58 | MAPT (0.50) | LMNANPC1RAB9APKMGAA | |
| SCHEMBL30218021 | 0.57 | MAP3K5 (0.34) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL31160431 | 0.57 | BACE1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059196-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-02-20 | — | — | US | disclosed |
| EP-4458819-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023125877-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059196-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | LMNA 2071/4885CDK8 171/4885MAPK14 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.